April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Long Term Experience With Adalimumab for Uvetitis
Author Affiliations & Notes
  • Peter G. Van Etten
    The Rotterdam Eyehospital, Rotterdam, The Netherlands
  • T Missotten
    The Rotterdam Eyehospital, Rotterdam, The Netherlands
  • P L. van Daele
    Internal Department/Clinical Immunology,
    Erasmus MC, Rotterdam, The Netherlands
  • G S. Baarsma
    The Rotterdam Eyehospital, Rotterdam, The Netherlands
  • R W. Kuijpers
    Ophthalmology,
    Erasmus MC, Rotterdam, The Netherlands
  • J A. van Laar
    Internal Department/Clinical Immunology,
    Erasmus MC, Rotterdam, The Netherlands
  • P M. van Hagen
    The Rotterdam Eyehospital, Rotterdam, The Netherlands
    Internal Department/Clinical Immunology,
    Erasmus MC, Rotterdam, The Netherlands
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter G. Van Etten, T Missotten, P L. van Daele, G S. Baarsma, R W. Kuijpers, J A. van Laar, P M. van Hagen; Long Term Experience With Adalimumab for Uvetitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the longterm efficacy and safety of Adalimumab for non-infectious uveitis.

 
Methods:
 

In this observational dynamic cohort 73 patients with refractory non-infectious uveitis who received subcutaneous Adalimumab in the period 2004 - 2010 were included. Refractory non-infectious uveitis was defined as failure on at least two other immunosuppressive drugs to control the uveitis episode or intolerance for current immunosuppressive drugs and/or failure to taper steroids. The visual acuity (VA), uveitis disease activity and cystoid macular edema (CME) were scored at a three months interval. Immunosuppressive co-medication and ocular surgery were allowed. Observed events during follow-up were registered and categorized in three groups: oncology related, infection related and miscellaneous.

 
Results:
 

142 eyes (73 patients, 41% man) were included. Mean age 40,4 years and mean follow up period 1.77 years (sd. 1.42). Mean VA at baseline was 0.48 logMAR (SEM 0.049; N=142), at 6 months 0,47 (SEM= 0.050; N=128), at 12 months 0,46 (SEM= 0.061; N=99) at 18 months 0,47 (SEM=0.075; N=76) and at 24 months 0,50 (SEM=0.093; N=49). Uveitis activity at baseline was present in 50,7% of patients and declined gradually (figuur 1). CME at baseline was present in 44.9% (SEM=0.042) and declined to 9% (SEM=0.043) at 24 months. Observed events: 5 infections with hospital admission, 1 malignancy (ovarian carcinoma), 8 others.

 
Conclusions:
 

Subcutaneous adalimumab is an effective (steroid-sparing) therapy in patients with refractory non-infectious uveitis. It is well tolerated and a relatively safe immunosuppressive drug.  

 
Keywords: uveitis-clinical/animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×